---

Endometrial Thickness — Clinical Reference Guide

Measurement Technique

---

1. Normal Physiological Variations

Premenopausal (by menstrual cycle phase)

Postmenopausal

The 4–5 mm threshold in symptomatic postmenopausal women is widely accepted (ACOG, RCOG guidelines) with a sensitivity of ~90–96% for endometrial carcinoma.

---

2. Pathological Conditions

---

3. Special Clinical Scenarios

Hormone-Related Changes

Fertility / ART Context

---

4. Risk of Malignancy by ET (Postmenopausal Women with Bleeding)

An ET > 20 mm in patients with preoperative AEH is highly predictive of concurrent occult endometrial cancer (confirmed as stage pT1a G2 in the image below). (pmc_clinical_VQA)

---

Ultrasound Example: AEH vs. Endometrial Cancer

---

Key Takeaways

• < 4 mm in a postmenopausal woman with bleeding = low malignancy risk (likely atrophy)
• > 4–5 mm with PMB = biopsy threshold
• > 20 mm = high suspicion for endometrial carcinoma regardless of symptoms
• Tamoxifen artificially thickens the apparent endometrium — sonohysterography is preferred in these patients
• In IVF, triple-line pattern with ET ≥ 8 mm is the goal for optimal implantation

---

Clinical Definition

• Diagnosis: In a woman with an intact uterus, menopause is a clinical diagnosis based on the absence of menstruation for at least 12 consecutive months, with no other pathological or physiological cause. (Treatment of Symptoms of the Menopause, p. 6)
• The average age of natural menopause is 51 years (range: 45–55).
• Hormonal measurements (FSH, LH, estradiol, inhibin B, AMH) are not required to confirm the diagnosis in typical cases.

---

Clinical Spectrum

---

Hormonal Changes

Hormonal testing is useful when the diagnosis is uncertain — e.g., in women who have had a hysterectomy (no menses to track), those under 40 (to diagnose POI), or those on hormonal contraception.

---

Common Symptoms

• Vasomotor: hot flushes, night sweats
• Genitourinary: vaginal dryness, dyspareunia, urinary urgency (GSM — genitourinary syndrome of menopause)
• Sleep disturbance, mood changes, cognitive symptoms
• Reduced libido
• Long-term: bone loss (osteoporosis), cardiovascular risk increase

---

Hormonal Changes in PCOS

Estrogen

• Estrone (E1) is elevated — due to peripheral conversion of androgens (androstenedione → estrone) in adipose tissue, particularly in overweight/obese women.
• Estradiol (E2) levels are typically in the low-to-normal follicular phase range, but there is a chronic, non-cyclic estrogen state — meaning estrogen is present continuously without the normal mid-cycle surge or luteal phase rise.
• There is no progesterone rise to oppose this estrogen, creating a state of unopposed estrogen — which increases the risk of endometrial hyperplasia and carcinoma.

---

Progesterone

• Decreased / Low — because ovulation does not occur (anovulation), the corpus luteum is not formed, so progesterone is not produced in the luteal phase.
• This results in irregular or absent menstruation (oligomenorrhea/amenorrhea).

---

FSH (Follicle-Stimulating Hormone)

• Low-normal or decreased relative to LH.
• FSH levels are insufficient to drive a dominant follicle to full maturity, leading to follicular arrest — multiple small antral follicles accumulate (the "polycystic" appearance on ultrasound).

---

LH (Luteinizing Hormone)

• Elevated — increased pulse frequency and amplitude of LH secretion from the pituitary.
• The classic finding is an elevated LH:FSH ratio (≥ 2:1 or ≥ 3:1), which is characteristic of PCOS, though not always present on a random measurement due to pulsatile secretion. (Harrison's Principles of Internal Medicine, 21st Ed., p. 11075)
• Elevated LH directly stimulates ovarian theca cells to produce excess androgens (testosterone, androstenedione).

---

Summary Table

---

The Core Hormonal Cascade in PCOS

↑ LH pulses
    → ↑ Theca cell androgen production (testosterone, androstenedione)
        → Peripheral conversion to estrone (↑ E1)
        → ↓ SHBG (especially with hyperinsulinemia) → ↑ free testosterone
            → Hyperandrogenism (clinical features)
            → Follicular arrest → anovulation → ↓ progesterone
                → Unopposed estrogen → endometrial hyperplasia risk

---

Top Diagnoses to Consider

1. Endometriosis / Adenomyosis (Most likely combined cause)

• Endometriosis causes HMB + dysmenorrhea + fornix tenderness — tender nodularity in the posterior/lateral fornix is a classic pelvic sign. (Endometriosis: Diagnosis and Management, p. 10)
• Adenomyosis (endometrial glands within myometrium) → bulky, tender uterus + heavy, painful periods.
• Ovarian endometrioma can cause adnexal/lateral fornix tenderness.

---

2. Pelvic Inflammatory Disease (PID)

• Adnexal tenderness (lateral fornix) + cervical motion tenderness are the hallmark examination findings of PID.
• Acute/subacute PID can cause menorrhagia due to endometritis.
• Associated features: purulent discharge, fever, raised CRP/WBC, history of STI.

---

3. Ectopic Pregnancy (Must exclude urgently)

• Lateral fornix/adnexal tenderness ± adnexal mass.
• Can present with abnormal uterine bleeding (usually not frank HMB, but irregular bleeding).
• Always check βhCG in any woman of reproductive age with pelvic pain + bleeding.

---

4. Ovarian Pathology

---

5. Uterine Fibroids (Leiomyomata)

• Submucosal and intramural fibroids are a major cause of HMB.
• Large broad ligament or lateral fibroids can cause lateral fornix/adnexal tenderness on palpation.

---

6. Coagulopathy / Bleeding Disorders

• Von Willebrand disease (VWD), factor XI deficiency, platelet dysfunction, and hemophilia carriers are common and underdiagnosed causes of HMB. (Harrison's, p. 1837)
• Defined as blood loss > 80 mL/cycle; clinical predictors include clots > 1 inch, changing pads hourly, iron-deficiency anaemia.
• These would not explain lateral fornix tenderness — if present alongside bleeding, a concurrent pelvic pathology must be sought.

---

7. Parametritis / Pelvic Abscess

• Infection spreading to parametrium → lateral fornix tenderness.
• Can follow PID, instrumentation (IUD insertion, post-abortion), or appendicitis.

---

Differential Summary Table

---

Immediate Priorities in Workup

1. βhCG — exclude ectopic pregnancy first
2. TVUS — assess endometrial thickness, adnexal masses, uterine morphology
3. Swabs (cervical/vaginal) — exclude PID/STI
4. FBC, ferritin — assess for iron-deficiency anaemia from HMB
5. Coagulation screen + VWF antigen/activity — if HMB since menarche or no structural cause found
6. CA-125 — if endometriosis or ovarian pathology suspected
7. MRI pelvis — gold standard for adenomyosis, deep infiltrating endometriosis

---

Key Distinction

In clinical practice, "regular" implies both cyclical and within normal parameters. "Cyclical" simply means the bleeding repeats in a pattern — it may still be irregular in timing.

---

Normal (Regular) Menstruation — Parameters

• Regular cycles become established 2–4 years after menarche.
• Cycle length shortens gradually after age 35.
• Anovulatory cycles increase as menopause approaches, making cycles erratic.

---

Types of Uterine Bleeding by Pattern

---

Cyclical vs. Regular — Clinical Significance

Cyclical but Irregular

• Occurs in PCOS, perimenopause, thyroid dysfunction, hyperprolactinaemia
• Bleeding repeats, but intervals are unpredictable (e.g., every 45–90 days)
• Often anovulatory — no progesterone produced → unopposed estrogen

Regular but Abnormal Volume/Duration

• Normal cycle timing but too heavy (fibroids, adenomyosis, coagulopathy) or too light (Asherman's syndrome, OCP)
• Ovulation is occurring normally — the problem is structural or local

Neither Cyclical nor Regular

• IMB, PCB, PMB — always require investigation to exclude malignancy, infection, or polyps

---

Summary

• Regular = predictable timing (25–35 days) — implies ovulation and a functioning HPO axis.
• Cyclical = repeating pattern — does not require normal interval or ovulation.
• All regular bleeding is cyclical, but not all cyclical bleeding is regular.
• Any deviation from regular, cyclical, normal-volume bleeding should be categorised using the FIGO PALM-COEIN classification of abnormal uterine bleeding (AUB) for systematic evaluation.